International Journal of Rheumatology

International Journal of Rheumatology / 2012 / Article
Special Issue

IgG4-Related Disease

View this Special Issue

Clinical Study | Open Access

Volume 2012 |Article ID 635473 | https://doi.org/10.1155/2012/635473

Masayuki Takahira, Yoshiaki Ozawa, Mitsuhiro Kawano, Yoh Zen, Shoko Hamaoka, Kazunori Yamada, Kazuhisa Sugiyama, "Clinical Aspects of IgG4-Related Orbital Inflammation in a Case Series of Ocular Adnexal Lymphoproliferative Disorders", International Journal of Rheumatology, vol. 2012, Article ID 635473, 5 pages, 2012. https://doi.org/10.1155/2012/635473

Clinical Aspects of IgG4-Related Orbital Inflammation in a Case Series of Ocular Adnexal Lymphoproliferative Disorders

Academic Editor: John H. Stone
Received28 Nov 2011
Accepted30 Jan 2012
Published02 Apr 2012

Abstract

The most frequent ocular adnexal tumors and simulating lesions are lymphoproliferative disorders (LPDs), including malignant lymphomas and orbital inflammation with lymphoid hyperplasia or infiltration. IgG4-related orbital inflammation (IgG4-ROI) often involves lacrimal glands and other orbital tissues and is an important differential diagnosis. The present study evaluated clinical aspects of IgG4-ROI in a case series of orbital LPD. Sixty-two consecutive cases of orbital LPD, pathologically diagnosed from November, 2004, through March, 2011, were investigated. Histological types were 22 cases with MALT lymphoma, 11 cases with diffuse large B-cell lymphoma (DLBCL), 3 cases with other malignant lymphomas, 16 cases with IgG4-ROI, and 10 cases with non-IgG4-ROI. Ages of the IgG4-ROI group (  yrs) were significantly lower than the MALT lymphoma (  yrs) and DLBCL (  yrs) groups. Orbital lesions other than lacrimal glands were present in six cases including extraocular muscle swelling, mass lesions surrounding the optic nerve, and supraorbital and infraorbital nerves enlargements. Although none of the malignant lymphomas were related to IgG4, previous evidence suggested that malignant lymphomas can arise from IgG4-ROI. Based on this study (26%) and another report (33%), it is likely that nearly a quarter of orbital LPD are IgG4-ROI.

1. Introduction

The most frequent tumors and simulating lesions in ocular adnexa are lymphoproliferative disorders (LPDs), including malignant lymphomas and orbital inflammation with lymphoid hyperplasia or infiltration, some of which are historically called “orbital pseudotumors.” In Japanese studies, Goto [1] reported that the rate of LPD among 409 cases with orbital tumors and simulating lesions was 43%, while Ohtsuka et al. [2] described that the rate was 49% out of 213 cases. In the United States, LPD is a common orbital disease although the rate seems to be somewhat lower: 24% of LPD out of 703 cases with orbital lesions was reported by Shields et al. [3], and 26% of LPD out of 268 cases was reported by Shinder et al. [4].

When patients with suspected orbital LPD are encountered, tissue biopsy is preferred since image examinations alone cannot distinguish inflammatory lesions from malignant lymphomas. Pathological examination can also detect whether the lesion is related to IgG4 or not. IgG4-related disease (IgG4-RD) often involves lacrimal glands, which is now known as IgG4-related Mikulicz’s disease [5, 6] or IgG4-related dacryoadenitis [7, 8] by many recent reports over several years. Recently, it was also elucidated that IgG4-related orbital inflammatory lesions include other ocular adnexal tissues such as extraocular muscles [9] and periorbital membrane [10]. Therefore, IgG4-RD is a differential diagnosis in orbital LPD. The question is then raised as to what percentage of orbital LPD is related to IgG4. In this study, an orbital LPD case series was investigated and clinical aspects of IgG4-related orbital lymphoproliferative disorders were evaluated.

2. Patients and Methods

In Kanazawa University Hospital in Japan, a 47-year-old woman with IgG4-immunopositive histopathology and an elevated serum IgG4 level of 1000 mg/dL was diagnosed as a first case of IgG4-related dacryoadenitis in November, 2004 [8]. From that time through March, 2011, sixty-two cases (27 men and 35 women; mean age, 66 ± 14 yrs; range 32–89 yrs) were pathologically diagnosed with orbital lymphoproliferative diseases (LPD) from surgical samples of ocular adnexal tissue. The two main categories of orbital LPD were malignant lymphomas and orbital inflammations: the latter included reactive lymphoid hyperplasia, lymphoid infiltrated lesions, and inflammatory pseudotumor. This consecutive 62 case series was investigated retrospectively. Conjunctival lesions were not enrolled in this study because conjunctival involvement in IgG4-RD has never been experienced in previous reports [9, 11] or in the author’s institution. Intraocular lymphoma belongs to CNS lymphoma and thus was also excluded in this study. In most cases, immunoglobulin heavy chain gene rearrangement in surgical samples was also examined to support the differential diagnosis of malignant lymphoma. Diagnostic criterion for positive IgG4-immunostaining in orbital tissue (IgG4-related orbital disease) was either (1) the ratio of IgG4-positive cells to IgG-positive cells (IgG4+/IgG+ cells) was more than 40% [12], or (2) the number of IgG4-positive cells was more than 30 per high power microscopy field [13]. Mouse monoclonal antibody anti-human IgG4 (05-3800, ZYMED, USA) and rabbit polyclonal antibody anti-human IgG (A0423, Dako, USA) were used for immunostaining. Serum IgG and IgG4 were measured in all of the cases with an IgG4-positive pathological diagnosis. IgG4-related orbital lesions including lacrimal gland swelling, extraocular muscle enlargement, and other mass lesions were evaluated using computed tomography (CT) and/or magnetic resonance imaging (MRI).

3. Results

Histological types of the 62 orbital LPD were 22 cases (35%) with extranodal marginal zone lymphoma of mucosa-associated lymphoid-tissue type (MALT lymphoma), 11 cases (18%) with diffuse large B-cell lymphoma (DLBCL), 3 cases (5%) with other malignant lymphomas (1 mantle cell lymphoma, 1 NK/T cell lymphoma, 1 small lymphocytic lymphoma), 16 cases (26%) with IgG4-related orbital inflammation (IgG4-ROI), and 10 cases (16%) with non-IgG4-related orbital inflammation (non-IgG4-ROI) (Figure 1). None of the malignant lymphomas showed a relationship with IgG4 in this case series. Figure 2 depicts the ages of the four groups of DLBCL, MALT lymphoma, IgG4-ROI, and non-IgG4-ROI. Ages of the IgG4-ROI group averaged 56 ± 10 yrs, which was significantly lower than those of the MALT lymphoma (71 ± 12 yrs, in a Student’s t-test) and DLBCL (75 ± 14 yrs, ) groups. There were no significant age differences between other combinations of the four groups.

Clinical data of sixteen cases of IgG4-ROI are summarized in Table 1, which were sorted in ascending order of serum IgG4 level. The age ranged between 41 to 76 yrs (mean ± SD; yrs, median; 58 yrs), and there was no sex difference (8 men and 8 women). These cases except one (number 1, detailed in the discussion) were accompanied by elevated serum IgG4 concentration (549 ± 293 mg/dL, , normal range < 135 mg/dL) and an increased ratio of serum IgG4/IgG (28 ± 12%, , normal range < 7%). In 9 patients, the serum IgE was also elevated. In all 16 cases, diagnosis was made by lacrimal gland biopsy. In pathology, these were characterized by lymphoplasmacytic infiltration, forming lymphoid follicles (germinal center) and sclerosing fibrosis [8]. IgG4-positive plasma cells were observed around lymphoid follicles and in intraglandular areas [8]. Orbital lesions other than lacrimal glands were detected by MRI in six cases (cases numbers 4, 7, 8, 11, 14, and 16 in Table 1) as shown representatively in Figure 3. Swollen extraocular muscles were seen in four cases (numbers 4, 7, 8 and 14). Supraorbital nerve (frontal nerve), and/or infraorbital nerve enlargements were observed in 4 cases (numbers 7, 8, 11, and 14). A mass lesion surrounding the optic nerve was detected in two patients (numbers 8 and 11).


Case numberAgeSexOrbital lesionsLesions other than orbitSerum IgG (mg/dL)Serum IgG4 (mg/dL)IgG4/IgG (%)IgG4 + cells /HPFSerum IgE (IU/mL)Therapy

162FLGNone16902924314None
266MLGSG196016481431621None
356FLGLung lesion16711941246254Steroid
446FLG, EOMSG, retroperitoneal fibrosis13502091592170Steroid
541FLGSinusitis15542601762178None
653FLGSG22603591658611Steroid
765MLG, EOM, IONSinusitis, submandibular lymphadenopathy144840428983374Steroid
860MLG, EOM, OPN, SON, IONSG, neck skin nodule122046338824608Steroid
964FLGSG, neck lymph nodes TB1820486278390Steroid
1066MLGSG, lung lesion, axillary lymphadenopathy19005753048151Steroid
1144MLG, OPN, IONNone13225994563351Steroid
1276FLGNephritis28607692758428Steroid
1360MLGSG,19528864548575Steroid
1445MLG, EOM, IONLung lesions, sinusitis2260914407472Steroid
1552MLGSG34409492850973Steroid
1647FLG, SON, IONSG235010004355183Steroid

Normal range870–1700<135<7<10<250

LG: lacrimal gland, EOM: extraocular muscle, OPN: optic nerve, SON: supraorbital nerve, ION: infraorbital nerve, SG: salivary gland.

Steroid therapy was performed for all the IgG4-ROI cases except three patients because their eyelid swellings decreased in size after biopsy surgery (case numbers 1, 2, and 5) and because of normal serum IgG4 (case number 1) and diabetes mellitus (case number 2). Eleven cases underwent oral prednisolone tapering therapy with an initial dose of 20, 30, or 40 mg per day. In two cases with diabetes mellitus, lower doses of oral prednisolone (10 mg daily in case number 10 and 8 mg daily in case number 15) were administered initially and reduced to a maintenance dose. All of the 11 cases essentially responded well to initial doses of oral prednisolone, but in 5 cases (numbers 4, 8, 10, 11, and 14) ocular symptoms such as eyelid swelling deteriorated during tapering, and thus increase in the dosage was required. In case number 11 with retrobulbar mass (Figure 3(c)), oral prednisolone therapy alone (30 mg daily initially) failed to diminish his exophthalmos, and then intravenous methylprednisolone pulse (500 mg for 3 days) was additionally performed three times.

4. Discussion

In this study, none of the malignant lymphoma cases was related to IgG4. However, some previous reports suggested that orbital malignant lymphomas can be related to IgG4. Cheuk reported three cases of ocular adnexal lymphoma (2 MALT lymphoma and 1 follicular lymphoma) arising in IgG4-related dacryoadenitis, and that the rate of transformation of malignant lymphoma in the background of IgG4-ROI was approximately 10% [12]. Sato et al. first detected IgH gene rearrangement in two cases of ocular adnexal IgG4-related disease [11] and later reported seven patients with ocular adnexal MALT lymphoma arising from IgG4-related orbital disease [14]. On the other hand, he described a case of IgG4-producing MALT lymphoma of the lymph node [15]. Also in the orbital region, Oyama reported a case of IgG4-expressing MALT lymphoma in the lacrimal gland [16]. Based on these findings, there could be two possibilities of orbital MALT lymphoma arising from preexisting IgG4-ROI and de novo IgG4-positive orbital MALT lymphoma [12]. In any case, orbital biopsy should be mandatory to evaluate malignancy before treatment even if serological examination already detected elevated serum IgG4.

There is no doubt that IgG4-ROI most frequently involves the lacrimal gland, which is reported as IgG4-related dacryoadenitis and Mikulicz’s disease [58]. In addition, lesions of IgG4-ROI other than the lacrimal glands were reported previously. Sato et al. reported that orbital masses other than the lacrimal gland were detected in 7 out of 21 cases with IgG4-ROI [11]. Kubota et al. reported a case with bilateral multiple extraocular muscle enlargement [9]. Mehta et al. presented a case of IgG4-ROI with enlargement of the infraorbital canal and periorbital membrane involvement [10]. Similar lesions were observed in the present case series of IgG4-ROI (Figure 3). In addition, mass lesions around the optic nerve were seen in two cases, indicating that involvement of the optic nerve sheath may not be rare in IgG4-ROI.

Among 16 cases of IgG4-ROI, one patient (case number 1) presented normal levels of serum IgG4. In this case, the ratio of IgG4+/IgG+ cells in immunohistochemistry was around 30%, somewhat lower than values in diagnostic criteria [6, 12], but IgG4-positive cells were more than 30 per high power microscopy field. The pathological findings that lymphoplasmacytic infiltration with germinal centers and dense sclerosing fibrosis was characteristic for IgG4-ROI. So far, we cannot resolve the reason for this discrepancy between pathological and serological findings. However, Kubota previously reported a patient with an inverse discrepancy who had negative findings on the IgG4 immunostaining despite presumably typical IgG4-ROI with elevated serum IgG4 [9].

The rate of IgG4-RD in 62 cases with orbital LPD was 26% in this study and was reported to be 33% out of 58 orbital LPD cases from another Japanese institute [17]. Thus, it is likely that nearly a quarter of orbital lymphoproliferative disorders are estimated to be related to IgG4. Further multicenter studies will be required to confirm this rate and to evaluate the frequency and location of IgG4-ROI other than the lacrimal glands.

References

  1. H. Goto, “Review of ocular tumor,” in Practical Ophthalmology, H. Goto, Ed., pp. 24–29, Bunkodo, Tokyo, Japan, 2008. View at: Google Scholar
  2. K. Ohtsuka, M. Hashimoto, and Y. Suzuki, “A review of 244 orbital tumors in Japanese patients during a 21-year period: origins and locations,” Japanese Journal of Ophthalmology, vol. 49, no. 1, pp. 49–55, 2005. View at: Publisher Site | Google Scholar
  3. J. A. Shields, C. L. Shields, and R. Scartozzi, “Survey of 1264 patients with orbital tumors and simulating lesions: the 2002 Montgomery Lecture, part 1,” Ophthalmology, vol. 111, no. 5, pp. 997–1008, 2004. View at: Publisher Site | Google Scholar
  4. R. Shinder, N. Al-Zubidi, and B. Esmaeli, “Survey of orbital tumors at a comprehensive cancer center in the United States,” Head and Neck, vol. 33, no. 5, pp. 610–614, 2011. View at: Publisher Site | Google Scholar
  5. M. Yamamoto, H. Takahashi, S. Sugai, and K. Imai, “Clinical and pathological characteristics of Mikulicz's disease (IgG4-related plasmacytic exocrinopathy),” Autoimmunity Reviews, vol. 4, no. 4, pp. 195–200, 2005. View at: Publisher Site | Google Scholar
  6. Y. Masaki, L. Dong, N. Kurose et al., “Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders,” Annals of the Rheumatic Diseases, vol. 68, no. 8, pp. 1310–1315, 2009. View at: Publisher Site | Google Scholar
  7. W. Cheuk, H. K. L. Yuen, and J. K. C. Chan, “Chronic sclerosing dacryoadenitis: part of the spectrum of IgG4-related sclerosing disease?” American Journal of Surgical Pathology, vol. 31, no. 4, pp. 643–645, 2007. View at: Publisher Site | Google Scholar
  8. M. Takahira, M. Kawano, Y. Zen, H. Minato, K. Yamada, and K. Sugiyama, “IgG4-related chronic sclerosing dacryoadenitis,” Archives of Ophthalmology, vol. 125, no. 11, pp. 1575–1578, 2007. View at: Publisher Site | Google Scholar
  9. T. Kubota, S. Moritani, M. Katayama, and H. Terasaki, “Ocular adnexal IgG4-related lymphoplasmacytic infiltrative disorder,” Archives of Ophthalmology, vol. 128, no. 5, pp. 577–584, 2010. View at: Publisher Site | Google Scholar
  10. M. Mehta, F. Jakobiec, and A. Fay, “Idiopathic fibroinflammatory disease of the face, eyelids, and periorbital membrane with immunoglobulin G4-positive plasma cells,” Archives of Pathology and Laboratory Medicine, vol. 133, no. 8, pp. 1251–1255, 2009. View at: Google Scholar
  11. Y. Sato, K. I. Ohshima, K. Ichimura et al., “Ocular adnexal IgG4-related disease has uniform clinicopathology,” Pathology International, vol. 58, no. 8, pp. 465–470, 2008. View at: Publisher Site | Google Scholar
  12. W. Cheuk, H. K. L. Yuen, A. C. L. Chan et al., “Ocular adnexal lymphoma associated with IgG4+ chronic sclerosing dacryoadenitis: a previously undescribed complication of IgG4-related sclerosing disease,” American Journal of Surgical Pathology, vol. 32, no. 8, pp. 1159–1167, 2008. View at: Publisher Site | Google Scholar
  13. T. Kamisawa, N. Funata, Y. Hayashi et al., “Close relationship between autoimmune pancreatitis and multifocal fibrosclerosis,” Gut, vol. 52, no. 5, pp. 683–687, 2003. View at: Publisher Site | Google Scholar
  14. Y. Sato, K. Notohara, M. Kojima, K. Takata, Y. Masaki, and T. Yoshino, “IgG4-related disease: historical overview and pathology of hematological disorders: review article,” Pathology International, vol. 60, no. 4, pp. 247–258, 2010. View at: Publisher Site | Google Scholar
  15. Y. Sato, K. Takata, K. Ichimura et al., “IgG4-producing marginal zone B-cell lymphoma,” International Journal of Hematology, vol. 88, no. 4, pp. 428–433, 2008. View at: Publisher Site | Google Scholar
  16. T. Oyama, J. Takizawa, N. Nakamura, S. Aoki, Y. Aizawa, and H. Abe, “Multifocal mucosa-associated lymphoid tissue lymphoma associated with IgG4-related disease: a case report,” Japanese Journal of Ophthalmology, vol. 55, no. 3, pp. 304–306, 2011. View at: Publisher Site | Google Scholar
  17. K. I. Ohshima, “Ocular adnexal IgG4-related disorders: do they overlap with Mikulicz's disease or MALT lymphoma?” Neuro-Ophthalmology Japan, vol. 25, no. 4, pp. 466–474, 2008. View at: Google Scholar

Copyright © 2012 Masayuki Takahira et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder
Views2504
Downloads921
Citations

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.